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A B S T R A C T
Background. Metabolism of glutamine by glutaminase 1 (GLS1) plays a key role in tumor cell proliferation via the generation of ATP and intermediates required for macromolecular synthesis. We hypothesized that glutamine metabolism also plays a role in proliferation of autosomal-dominant polycystic kidney disease (ADPKD) cells and that inhibiting GLS1 could slow cyst growth in animal models of ADPKD. Methods. Primary normal human kidney and ADPKD human cyst-lining epithelial cells were cultured in the presence or absence of two pharmacologic inhibitors of GLS1, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) and CB-839, and the effect on proliferation, cyst growth in collagen and activation of downstream signaling pathways were assessed. We then determined if inhibiting GLS1 in vivo with CB-839 in the Aqp2-Cre; Pkd1 fl/fl and Pkhd1-Cre; Pkd1 fl/fl mouse models of ADPKD slowed cyst growth. Results. We found that an isoform of GLS1 (GLS1-GAC) is upregulated in cyst-lining epithelia in human ADPKD kidneys and in mouse models of ADPKD. Both BPTES and CB-839 blocked forskolin-induced cyst formation in vitro. Inhibiting GLS1 in vivo with CB-839 led to variable outcomes in two mouse models of ADPKD. CB-839 slowed cyst growth in Aqp2-Cre; Pkd1 fl/fl mice, but not in Pkhd1-Cre; Pkd1 fl/fl mice. While CB-839 inhibited mammalian target of rapamycin (mTOR) and MEK activation in Aqp2-Cre; Pkd1 fl/fl ADPKD is caused by mutations in one of two genes, PKD1 or PKD2, which encode polycystin 1 (PC1) and polycystin 2 (PC2), respectively [1, 2] . Loss of both copies of PKD1 or PKD2 is associated with cyst initiation and cyst enlargement by stimulating the enhanced growth of renal epithelia as well as the stimulation of apical chloride secretion via the cystic fibrosis transmembrane conductance regulator (CFTR).
Altered regulation of a number of different signaling pathways and transcription factors has been identified in ADPKD that may account for proliferation and cyst formation [3, 4] . Interestingly, many of these signaling pathways mirror changes found in cancer cells [4] . Recent evidence has indicated that tumor cells undergoing increased growth and division exhibit marked changes in cellular metabolism which intersect with known signaling pathways that have been implicated in the proliferation of ADPKD cells [3, 5, 6] . In this regard, two recent papers have demonstrated an increase in glycolytic flux in PKD cells and kidneys, and inhibiting this by the administration of 2-deoxy-D-glucose slowed cyst growth in several animal models of ADPKD [7, 8] .
Glutamine is the most abundant amino acid in plasma and has emerged as one of the key nutrients required to support growth of some cancer cells [9] [10] [11] [12] . Glutaminase catalyzes the first step in glutamine metabolism, converting glutamine to glutamate. Glutamate is subsequently catabolized to a-ketoglutarate (aKG), a key intermediate in the TCA cycle to generate ATP as well as the carbon backbone for cellular anabolic processes [9] . There are two distinct but related Gls genes, GLS1 and GLS2 [13] [14] [15] . GLS2 is expressed highly in the liver, whereas GLS1 is more broadly expressed. GLS1 has two spliced variants: KGA, which is the kidney-specific isoform that mediates ammonia generation for acid secretion, and GAC, which has been shown to be upregulated in cancer cells and is thought to play a role in glutaminolysis [16] [17] [18] .
GLS1 has emerged as a promising therapeutic drug target to treat a variety of different cancers [19] . Studies have shown that interfering with GLS1 activity by siRNA knockdown, genetically, or by pharmacologic inhibition slows cancer cell growth in vitro and in vivo in murine models of cancer [16, 17, 20, 21] . bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) is an allosteric specific GLS1 inhibitor that on crystal structure was shown to dock at the tetrameric interfaces and locks GLS1 in an inactive state [22, 23] . CB-839 is a selective oral GLS1 inhibitor that has shown improved potency and bioavailability in animal models compared with BPTES [16, 20] and is currently in Phase 1 clinical trial for cancer treatment. We hypothesized that glutamine metabolism also plays a critical role in proliferation of ADPKD cells and that inhibitors of glutamine metabolism and more specifically GLS1 could be a potential new target to slow cyst growth in patients with ADPKD.
M A T E R I A L S A N D M E T H O D S

Cell culture
Primary cultures of ADPKD cells were generated by the PKD Biomaterials and Cellular Models Core at the University of Kansas Medical Center, as previously described [24, 25] . Briefly, primary cell cultures were derived from normal regions of nephrectomy specimens confirmed by histological examination, or surface cysts of ADPKD kidneys. These cell lines have characteristics of collecting duct cells, in that they stain positive for cytokeratin and Dolichus biflorus agglutinin. Cells were maintained in DMEM/F12 supplemented with 10% FBS, insulin (5 lg/mL)/transferrin (5 lg/mL)/selenium (5 ng/ mL) (Gibco) and used up to Passage 4.
Cyst growth in collagen gel and cyst number ADPKD and normal human kidney (NHK) cells were seeded within collagen and stimulated with forskolin (10 lmol) as described [24] [25] [26] . Briefly, 800 cells were mixed with 0.4 mL of ice-cold PureCol collagen (3.0 mg/mL collagen; Advanced Biomatrix) supplemented with 10% (v/v) 10Â minimum essential medium, HEPES (10 mM), NaHCO 3 (27 mM), penicillin and streptomycin and plated into 24-well plates. Cells were stimulated with forskolin (10 lM) in the presence or absence of the GLS1 inhibitor BPTES or CB-839 and cyst formation was assessed on Day 16. On Day 16 of culture, the 24-well plate was placed on the stage of an inverted microscope and the number of cysts in each well was counted; the diameter of each cyst was measured using an ocular scale at 40Â as previously described [26] . Only cysts larger than 100 lm were clearly identified and counted as previously reported [26] .
siRNA knockdown of GLS1 was performed by transfecting NHK and ADPKD cells with either of the two siRNA to GLS1 (25 nM) fl/fl male mice frequently had only minimal cysts at this time and progressed to renal failure at a much slower and more unpredictable rate overall. The reason for the differences are not apparent but is likely related to differences in Cre expression between female and male mice.
All animals were used in accordance with scientific, humane and ethical principles and in compliance with regulations approved by the New York University School of Medicine Institutional Animal Care and Use Committee.
Cystic index and kidney immunohistochemistry
Kidneys from both models were harvested, fixed in 4% paraformaldehyde for 4 h at 4 C, and sagittal kidney sections were stained with hematoxylin and eosin. Sections were then photographed under the same magnification and cystic index was calculated using ImageJ analysis software on two sagittal sections/ kidney as described [28] . Cystic index was calculated as the cumulative cyst volume per total area of kidney.
Kidney immunohistochemistry was performed on ADPKD and NHKs obtained from nephrectomy, and kidneys from WT (Pkd1 fl/fl ) and Aqp2-Cre; Pkd1 fl/fl and Pkhd1-Cre; Pkd1 fl/fl mice. Immunohistochemistry was performed on 4-mm formalinfixed, paraffin-embedded kidney sections using antibodies as indicated. Chromogenic immunohistochemistry was performed on a Ventana Medical Systems Discovery XT platform with online deparaffinization, antigen retrieval and using Ventana's reagents and detection kits. In brief, heat-mediated antigen retrieval was performed using either CC1 (TrisBorate-EDTA, pH 8.5) or RCC2 (sodium citrate pH 6.0) as required. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Primary antibodies were diluted in Dulbecco's phosphate-buffered saline (Life Technologies) 3 h at 37 C and detected using anti-rabbit or anti-mouse HRP-labeled multimers incubated for 8 min. The complex was visualized with 3,3 diaminobenzidene and enhanced with copper sulfate.
Seahorse oxygen consumption rates
Cells were seeded (10 000-15 000 cells/well) on XF e 24 plates (Seahorse Biosciences) in complete medium in the presence or absence of CB-839 (1 lM) and forskolin (10 lg/mL) and allowed to attach overnight. The cells were then placed in fresh medium lacking FBS, incubated without CO 2 for 1 h, and oxygen consumption rates was then determined at baseline and following the sequential addition of oligomycin (1 mg/mL), carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) (125 nM) and antimycin (1 mmol/L) as per the manufacturer's protocol.
Glutamine starvation, anti-phospho-S6 staining and immunofluorescence NHK and ADPKD cells were cultured for 24 h in media lacking glutamine (Q) and leucine (L). L is added together with Q as L is required to activate glutamine dehydrogenase, which converts glutamate to a-KG [30] . Cells were then placed in media containing Q and L for 1 h, lysed and immunoblotted with anti-phospho-S6 antibodies or fixed in 4% paraformaldehyde and then stained with primary anti-mTOR and anti-LAMP2 antibodies followed by secondary anti-mouse fluorescein isothiocyanate (FITC) or CY3 antibodies. Cells were then imaged with a Zeiss 710 confocal microscope.
Western analysis
Kidneys harvested at time of sacrifice were flash frozen in liquid nitrogen, homogenized in lysis buffer, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE), immunoblotted with primary antibody as indicated and detected with an Li-cor IRdye secondary antibody as described [29] .
R E S U L T S
The GLS1 GAC isoform is upregulated in cyst-lining epithelia in kidneys from patients with ADPKD
To assess the expression of GLS1 isoforms, NHK and kidneys from patients with ADPKD were stained with specific antibodies to GLS1 KGA or GLS1 GAC. We found that KGA is the predominant isoform expressed in tubule cells in NHK, while GAC expression was much more limited ( Figure 1 ). In contrast, >70% of cyst-lining epithelia in human ADPKD kidneys had upregulated GAC protein expression ( Figure 1A ), indicating that increased GLS1 GAC expression was associated with renal cyst formation. Increased GLS1 GAC expression was also seen in two mouse models of ADPKD ( Figure 1B and C).
GLS1 is required for cyst growth by human ADPKD cells in collagen gels
Primary human ADPKD cells have previously been found to be a good model for investigating cellular mechanism involved in cyst growth [24, 25] . In contrast to the studies in Figure 1 , we found that both the GAC and KGA isoforms of GLS1 are expressed in roughly equal amounts in primary ADPKD and NHK cells isolated from cyst lining (Figure 2A ). In addition, treatment with the potent cyclic AMP agonist forskolin did not affect the expression of either GLS1 isoform in either NHK or ADPKD cells (Figure 2A ). We next tested if GLS1 inhibition with BPTES and CB-839-affected cell proliferation and cyst formation of NHK and ADPKD cells. BPTES and CB-839 inhibited cell proliferation ( Figure 2B ) and the size and number of cysts of both ADPKD cells ( Figure 2C -E) and NHK (data not shown) cells when cells were seeded within a collagen matrix and stimulated with forskolin to form cysts [24] [25] [26] . Cyst formation was also inhibited by growing cells in glutaminedeprived medium ( Figure 2F ).
To confirm that GLS1 was the drug target and is essential for cyst growth, ADPKD cells were transfected with two different siRNA to GLS1 ( Figure 2G and H). siRNA knockdown of GLS1 also led to a statistically significant decrease in cyst formation ( Figure 2G and H). The inhibition of cyst formation by GLS1 siRNA ( Figure 2G and H) and proliferation by BPTES ( Figure 2B ) was specific to GLS1 inhibition and not an off-target effect as addition of dimethyl-aKG to the medium, which functions downstream of GLS1, resulted in a significant rescue of cyst formation in siRNA-transfected cells and proliferation in BPTES-treated ADPKD or NHK cells (data not shown).
To address the mechanisms whereby GLS1 inhibition limits cyst growth in vitro, Seahorse analysis was performed to assess mitochondrial respiration. Forskolin stimulation led to an increase in both the basal and maximal mitochodrial O 2 consumption in ADPKD and NHK cells ( Figure 3A and B) and treatment with CB-839 led to a statistically significant inhibition of basal and maximal mitochodrial O 2 consumption of both unstimulated and forskolin-stimulated ADPKD and NHK cells ( Figure 3A and B) . Glutamine metabolism via generation (J) siRNA to GLS1 decreased protein expression of GLS1 on Days 3 and 8 post-transfection shown as quantification derived from ratio of net GLS1 to net loading control actin. Differences were evaluated by one-way analysis of variance (ANOVA) using Bonferroni test (*P < 0.05, **P < 0.01, ***P < 0.001). All results are representative of three independent experiments of primary ADPKD cells isolated from three independent patients.
Glutamine metabolism and ADPKD . Results are representative of three independent experiments of primary ADPKD and NHK cells isolated from three independent patients. Differences were evaluated by two-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (C, D) ADPKD and NHK cells were deprived of glutamine (Q) or leucine (L) for 24 h and then incubated with Q and L for 60 min in the absence or presence of BPTES (20 lM), CB-839 (1 lM) or rapamycin, and lysates were immunoblotted with anti-pS6 antibodies. L is added together with Q as L is required to activate glutamate dehydrogenase which converts glutamate to aKG [30] . To control for protein loading, cell lysates were also probed with anti-actin antibody. Western blot of phospho-S6 to loading control actin was quantified using ImageJ. The quantification values shown below each band are the ratio of net phospho S6 to net actin. (E) Cells were treated as in (C) and (D), fixed in 4% paraformaldehyde and stained with mouse anti-mTOR and rabbit anti-LAMP2 antibodies followed by Cy3 anti-mouse or FITC anti-rabbit secondary antibodies. Images were captured using a Zeiss 710 confocal microscope. Scale bar represents 100 lm.
of a-KG has previously been shown to mediate amino acid activation of mTORC1 in some cancer cells by simulating the recruitment of mTORC1 to the lysosome [30] . Treatment with BPTES or CB-839 also inhibited amino acid activation of mTORC1 in ADPKD and NHK cells as assessed by pS6 immunoblot ( Figure 3C and D) . In additon, inhibition of mTORC1 was associated with decreased recruitment of mTOR to the lysosome ( Figure 3E ). Figure 5 ). While Pkhd1-Cre also expresses predominantly in collecting duct principal cells, this model has been shown to give a robust and a very reproducible phenotype [27] . However, in contrast to Aqp2-Cre; Pkd1 fl/fl mice, CB-839 treatment did not slow cyst growth or preserve renal function in Pkhd1-Cre; Pkd1 fl/fl mice ( Figure 5A-D) despite >75% inhibition of GLS1 enzyme activity in treated kidneys ( Figure 5E ). Consistent with the inhibition of GLS1, CB-839-treated kidneys had elevated glutamine to glutamate ratio compared with vehicle-treated Pkhd1-Cre; Pkd1 fl/fl kidneys ( Figure 5F ). Moreover CB-839 levels in Pkhd1-Cre; Pkd1 fl/fl kidneys were 15.4 6 SEM 3.18 nmol/g, which is significantly >1.5 nmol/g of CB-839 found in tumors and which led to a slowing of tumor growth in vivo [16] . Thus, the failure of CB-839 to block cyst growth in Pkhd1-Cre; Pkd1 fl/fl kidneys was not due to under-dosing of drug or the failure to inhibit kidney GLS1 in vivo.
As shown in Figure 1B and C, increased GLS1 GAC expression in cyst-lining epithelia was seen in both models and, therefore, differences in GLS1 GAC protein expression do not account for the differential response. Consistent with the increase in GAC expression, GLS1 enzyme activity was approximately two times greater in Pkhd1-Cre; Pkd1 fl/fl kidneys compared with wild type (WT) kidneys ( Figure 5E ). Activation of mTOR and B-RAF-ERK-MAPK mediate cyst growth in some models of ADPKD [3, 31] . We found that mTOR activity was increased in most kidneys from vehicle-treated Aqp2-Cre; Pkd1 fl/fl mice when compared with kidneys from vehicle-treated WT (Pkd1 fl/fl ) mice and treatment with CB-839 inhibited mTOR activation in Aqp2-Cre; Pkd1 fl/fl kidneys as assessed by phospho-S6 expression ( Figure 6 ). In addition, phospho-MEK and phospho-ERK were also increased in most kidneys from vehicle-treated Aqp2-Cre; Pkd1 fl/fl mice and the increase in phospho-MEK, but not phospho-ERK, was inhibited by CB-839 ( Figure 6 ). In contrast, phospho-S6 was not increased in kidneys from both vehicle and CB-839-treated Pkhd1-Cre; Pkd1 fl/fl mice when compared with kidneys from vehicle-treated WT (Pkd1 fl/fl ) mice (Figure 6 ). In addition, while phospho-MEK and phospho-ERK were increased in vehicle-treated Pkhd1-Cre; Pkd1 fl/fl kidneys when compared with vehicletreated Pkd1 fl/fl mice kidneys, treatment with CB-839 did not inhibit the increase in either phospho-MEK or phospho-ERK ( Figure 6 ). These results suggest that differential activation and inhibition of mTOR and MEK may account for slowing of cyst growth by CB-839 in Aqp2-Cre; Pkd1 fl/fl but not in Pkhd1-Cre; Pkd1 fl/fl mice.
D I S C U S S I O N
Although ADPKD cells depend on many of the same signaling pathways as cancer cells for proliferation and cyst formation, the role for altered metabolism in ADPKD pathogenesis has been largely unexplored. Recent studies have indicated that altered glucose and lipid metabolism may contribute to cyst formation in PKD [7, 8, 32, 33] . To begin to address whether PKD cells may be uniquely dependent upon glutamine metabolism via GLS1 for cell growth and cyst formation, we assessed whether GLS1 inhibition slows cyst growth in vitro in primary human ADPKD and NHK cells and in vivo in two mouse models of PKD. We found that inhibiting GLS1 slowed cyst growth in vitro, although we did not detect differences between ADPKD and fl/fl kidneys treated with vehicle or 2 h following treatment with CB-839. Differences were evaluated by two-tailed t-tests (*P < 0.05, **P < 0.01; ns, not significant).
NHK cells. In addition, we found that GLS1 inhibition in vitro was associated with impaired mitochondrial respiration and decreased activation of mTOR by amino acids, suggesting that inhibiting glutamine metabolism has the potential to impair cyst growth by simultaneously blocking several nonoverlapping pathways proposed to play a role in proliferation of cyst-lining epithelia. While ideally we would have liked to see differences between ADPKD and NHK cells, the finding that GLS1 inhibition slowed growth of kidney tubule cells is not insignificant given that many primary cells, cell lines and cancer cells are not dependent upon glutamine metabolism via GLS1 for cell growth as they are able to utilize other nutrients and pathways to generate intermediates of the tricarboxylic acid (TCA) cycle, ATP and carbon and nitrogen intermediates for macromolecular synthesis and cell growth [16, 20, 34, 35] .
Despite the failure to see differences between ADPKD and NHK cells in culture, we felt it was still critical to explore whether inhibition of GLS1 slows cyst growth in animal models of PKD for the following reasons. We found marked upregulation of the GLS1 GAC isoform in cyst-lining epithelia in kidneys from both (B, C) Quantification of western blots using ImageJ. The quantification values are the ratio of net band to net loading control as shown in the graph (n ¼ 5). Differences were evaluated by two-tailed t-tests (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant).
human ADPKD and several mouse models of PKD; increased expression of GLS1 GAC isoform in cancer cells is associated with glutamine dependency and response to GLS1 inhibition in many studies [16, 17, 36] . The increase in GLS1 GAC in tumors has been linked to upregulation of Myc, which is consistent with previous findings that Myc is upregulated in PKD kidneys and plays a role in pathogenesis [33, [37] [38] [39] . In addition, changes in cell culture may not reflect the local environment in vivo that cyst-lining epithelia is subjected to as a result of altered kidney morphology and blood supply, which is supported by many studies of cancer cells demonstrating that metabolic changes observed in vitro do not reflect changes in vivo [40] .
We found that inhibiting GLS1 in vivo with the GLS1 inhibitor CB-839 led to variable outcomes in two mouse models of ADPKD. While inhibiting GLS1 slowed cyst growth in the less aggressive cystic disease in Aqp2-Cre; Pkd1 fl/fl mice, it did not slow cyst growth in the more aggressive Pkhd1-Cre; Pkd1 fl/fl cystic model despite >75% inhibition of GLS1 enzyme activity in Pkhd1-Cre; Pkd1 fl/fl kidneys, indicating that failure to inhibit GLS1 or to achieve significant levels of CB-839 in Pkhd1-Cre; Pkd1 fl/fl kidney does not account for negative results. The reasons for these differences are not apparent, although we have identified differences in signaling pathways activated in the two models and in differences in GLS1 inhibition of these pathways. mTOR was activated in kidneys from Aqp2-Cre; Pkd1 fl/fl , but not Pkhd1-Cre; Pkd1 fl/fl mice, as assessed by increase in phospho-S6, and the increase in phospho-S6 in Aqp2-Cre; Pkd1 fl/fl kidneys was inhibited by CB-839. In addition, an increase in phospho-MEK and phospho-ERK was observed in most kidneys in both models, although CB-839 inhibited the increase in phospho-MEK only in kidneys from Aqp2-Cre; Pkd1 fl/fl mice suggesting that inhibition of MEK by CB-839 may also contribute to slowing of cyst growth in Aqp2-Cre; Pkd1 fl/fl mice. Previously, Pkd1 -/-MEFs were shown to undergo aerobic glycolysis similar to cancer cells, as described by Warburg [7, 41] . These cells had increased glucose uptake and metabolism, elevated ATP generation and mTOR activity and inhibition of glycolysis in vivo with 2-deoxyglucose in both early rapid mouse models of ADPKD [7] and more recently in a more slowly progressive and late-onset model [8] slowed cyst growth. Another recent study identified alterations in lipid metabolism in PKD kidneys and slowing of cyst growth when mice were placed on a diet containing a lower lipid content [32] .
Our findings provide support that alteration in other metabolic pathways, such as glutamine metabolism, may play a role in cyst growth and targeting these pathways either alone or together with inhibitors of other pathways [42] has the potential to slow cyst growth in patients with ADPKD. This is consistent with a previous report demonstrating increased 2-hydroxyglutarate in kidneys from cpk mice, a mouse model of autosomal recessive kidney disease [43] . However, our results highlight the variability in response of different mouse models of PKD to inhibition of the same metabolic drug target, which would be consistent with the broad and variable range of metabolic changes so far identified in cancer cells and the variability in response to GLS1 inhibition in vivo and in vitro due to upregulation of adaptive metabolic networks that bypass GLS1 inhibition [42, 44, 45] . It remains to be determined which adaptive changes bypass GLS1 inhibition in PKD. Previous studies have demonstrated that glutamine metabolism via GLS1 serves as an important carbon source for the TCA cycle and, consistent with this, treatment with GLS1 inhibitors led to decreased oxidative phosphorylation (OXPHOS) in a variety of tumor cell lines [15, 34] ; a-KG, which is generated from glutamate by either glutamate dehydrogenase or aminotransferases, feeds directly into the TCA cycle [46] . In addition, increase in reactive oxygen species (ROS) following GLS1 inhibition has been shown to indirectly decrease OXPHOS by impairing carbohydrate flux and thereby glucose flux into the TCA cycle via inhibition of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [34, 47] . We found a similar decrease on OXPHOS by inhibiting GLS1 in ADPKD cells in vitro. The failure of CB-839 to inhibit cyst growth in vivo in Pkhd1-Cre; Pkd1 fl/fl mice as opposed to Aqp2-Cre; Pkd1 fl/fl mice could be due to glycolysis playing a predominant role in the former as has been reported for carcinomas that do not respond to GLS1 inhibition [42] . Tumor cells also adapt to GLS1 inhibition via upregulation of arginine metabolism. Two recent papers have found that PKD cells have decreased OXPHOS when compared with WT cells [33, 48] . Hajarnis et al. found that the decrease in OXPHOS is mediated by upregulation of the messenger RNA miR-17, which then secondarily led to the downregulation of peroxisome proliferatoractivated receptor (PPAR), and decreasing miR-17 with an anti-miR-17 slowed cyst growth in vivo and in vitro [33] . In contrast to our findings reported here, the beneficial effect of inhibiting miR17 was associated with increased OXPHOS, which the authors proposed could impede cyst growth by limiting the amount of carbon available to be shuttled into alternative metabolic pathways. Inhibiting glutamine metabolism will similarly limit the available carbon and nitrogen atoms for other metabolic pathways, albeit with a divergent effect on OXPHOS.
Validation of GLS1 as potential therapeutic drug targets will require broadly profiling the metabolic changes in kidneys from additional models of PKD and from patients to determine which rodent models best reflect changes in human ADPKD kidneys. These studies will also be critical to identify the compensatory metabolic changes that bypass GLS1 inhibition so that rationale combination therapies may be tested.
F U N D I N G
